Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683704 | 0.80 | MAPT (0.35) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL579295 | 0.78 | ACLY (0.40) | RAB9ANPC1 | |
| SCHEMBL5634574 | 0.77 | HTR2A (0.46) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL4052956 | 0.77 | DAO (0.37) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL4047939 | 0.76 | HTR2A (0.34) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL18498836 | 0.74 | FABP4 (0.45) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL4379598 | 0.74 | MCL1 (0.47) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL29798163 | 0.74 | FABP4 (0.45) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL17674406 | 0.74 | TFPI2 (0.55) | TFPI2RAB9ATSHRL3MBTL1OXER1 | |
| SCHEMBL18832074 | 0.74 | KMO (0.42) | TFPI2RAB9ATSHRL3MBTL1OXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | TFPI2 645/4885RAB9A 379/4885TSHR 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.